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 Cardiovascular disease (CVD) is the leading cause of 
death and disability in the United States. Obesity is associ-
ated with hypertension, diabetes, elevated triglyceride 
(TG) levels, and decreased HDL-cholesterol (HDL-C) lev-
els, all acknowledged as independent CVD risk factors by 
the AHA ( 1 ). Obesity, defi ned by body mass index (BMI)   
30 kg/m 2 , often coexists with the metabolic syndrome, 
which is associated with increased CVD risk. High BMI has 
been associated with increased risk for the development of 
coronary, cerebral, and peripheral vascular disease; how-
ever, due to the coexistence of multiple risk factors, the 
quantitative assessment of CVD risk exclusively associated 
with obesity is complicated. 
 Bariatric surgery is an effective intervention to achieve 
long-term marked weight reduction in patients with morbid 
obesity ( 2, 3 ). It has recently been published that calculated 
10 year CVD risk (based on the Framingham equation) in 
morbidly obese subjects decreased by 1.3% 12 months after 
laparoscopic Roux-en-Y gastric bypass (RYGBP) surgery ( 4 ) 
and that substantial weight loss, following RYGBP surgery, 
 Abstract  Plasma lipoproteins and glucose homeostasis 
were evaluated after marked weight loss before and over 12 
months following Roux-en-Y gastric-bypass (RYGBP) surgery 
in 19 morbidly obese women. Standard lipids, remnant-lipo-
protein cholesterol (RLP-C); HDL-triglyceride (TG); apoli-
poproteins (apo) A-I, A-II, E, and A-I-containing HDL 
subpopulations; lecithin-cholesterol acyltransferase (LCAT) 
and cholesteryl ester transfer protein ( CETP) mass and 
activity; plasma glucose and insulin levels were measured 
before and at 1, 3, 6, and 12 months after GBP surgery. 
Baseline concentrations of TG, RLP-C, glucose, and insulin 
were signifi cantly higher in obese than in normal-weight, 
age-matched women, whereas HDL cholesterol (HDL-C), 
apoA-I, apoA-II,   -1 and   -2 levels were signifi cantly lower. 
Over 1 year, signifi cant decreases of body mass index, glu-
cose, insulin, TG, RLP-C, HDL-TG, and pre  -1 levels were 
observed with signifi cant increases of HDL-C and   -1 levels 
(all  P < 0.05). Changes of fat mass were correlated with 
those of LDL cholesterol ( P = 0.018) and LCAT mass ( P = 
0.011), but not with CETP mass ( P = 0.265). Changes of fast-
ing plasma glucose concentrations were inversely correlated 
with those of CETP mass ( P = 0.005) and   -1 level ( P = 
0.004). Changes of fasting plasma insulin concentrations 
were positively correlated with those of LCAT mass ( P = 
0.043) and inversely with changes of   -1 ( P = 0.03) and   -2 
( P = 0.05) concentrations.  These results demonstrate ben-
efi cial changes in HDL remodeling following substantial 
weight loss induced by RYGBP surgery and that these 
changes are associated with improvement of glucose ho-
meostasis in these patients. —Asztalos, B. F., M. M. Swarbrick, 
E. J. Schaefer, G. E. Dallal, K. V. Horvath, M. Ai, K. L. 
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(Richmond, VA). Lecithin-cholesterol acyltransferase (LCAT) 
and cholesterol ester (CE) transfer protein (CETP) activities 
were determined as described by Fielding ( 22, 23 ). The principle 
of this method is that the increased CE in plasma, incubated in 
vitro, as a result of LCAT activity is associated with an equivalent 
molar decrease in free cholesterol (FC). The rate of CETP-mediated 
transfer of CE from HDL to very low density lipoprotein (VLDL)
and LDL is then the difference between the rate of decrease in 
FC in whole plasma, and the rate of increase of CE in HDL, as a 
function of time. This assay provides unique information on the 
interplay between LCAT and CETP by measuring total-C and FC 
in total plasma and in apoB-depleted plasma at two time points 
[time 0 (initial) and after 3 h of incubation at 37°C (fi nal)]. Molar 
CETP activity = [(initial plasma FC – fi nal plasma FC)] – [(fi nal 
HDL-TC – fi nal HDL-FC) – (initial HDL-TC – initial HDL-FC)]. 
LCAT activity was assessed as the difference between initial plasma 
FC and fi nal plasma FC as a function of time. All measurements 
were performed on a Hitachi 911 analyzer with inter-assay coef-
fi cients of variation <5% in the Lipid Metabolism Laboratory at 
Tufts University in Boston. CETP and LCAT masses were measured 
by ELISA kits obtained from Wako Diagnostics (Richmond, VA) 
and Alpco Diagnostics (Salem, NH), respectively. 
 Insulin was measured by radioimmunoassay (Linco, St. 
Charles, MO), and glucose was measured with a glucose analyzer 
(YSI, Yellow Springs, OH). Homeostatic model assessment of 
insulin resistance (HOMA-IR) was calculated as previously de-
scribed ( 24 ). 
 ApoA-I-containing HDL subpopulations were determined by 
2-dimensional nondenaturing gel electrophoresis, immunoblot-
ting, and image analysis as described ( 25, 26 ). ApoA-I levels in 
the individual HDL subpopulations were calculated by multi-
plying plasma apoA-I levels by the subpopulation percentiles. 
Because each HDL particle has a fi xed number of apoA-I mole-
cules, the change in apoA-I levels in each HDL subpopulation 
is proportional to changes in particle numbers. The inter- and 
intra-assay coeffi cients of variation were <10% for the HDL sub-
population determinations. All plasma samples were stored at 
–80°C and were never thawed until analysis. ApoA-IV- and 
apoE-containing HDL subpopulations were determined by 
2-dimensional nondenaturing gel electrophoresis followed by im-
munoblotting for apoA-IV and apoE, respectively, and image anal-
ysis. ApoE-containing HDL particles were calculated as “large 
apoE HDL” with sizes >11 nm and “small apoE HDL” with sizes 
<11 nm. It is worth noting that all large apoE HDL are probably 
highly lipidated, whereas the tight band appearance of the small 
apoE HDL particles indicates that those are aggregates of lipid-
poor apoE. 
 Statistical analysis 
 All data were calculated as mean ± SD. Due to nonparametric 
distribution, TG data were log-transformed before analyses. Dif-
ferences were determined from analyses of log-transformed data. 
Differences between means were calculated by the two-sided  P < 
0.05, Tukey’s Honestly Signifi cant Difference test. Overall 
changes were calculated by 32 repeated ANOVAs (adjusted for 
BMI) for the hypothesis of no change over time. Matrix analyses 
(nonparametric) were used for calculating associations between 
selected variables. The SAS statistical package was used in all sta-
tistical analyses. The best fi t curve was calculated using the Stat-
Most statistical program. 
 RESULTS 
 The anthropometric characteristics and parameters 
related to lipid and glucose metabolism measured in 
decreased overall mortality ( 5 ) and often resulted in sig-
nifi cant improvements in lipid parameters and CVD risk 
( 6–10 ). Increased circulating adiponectin concentrations, 
improvements of insulin sensitivity, decreased heart rate 
and hypertension, and other comorbidities of severe obesity 
have also been shown to accompany substantial weight loss 
after RYGBP surgery ( 11–16 ). 
 Elevated LDL cholesterol (LDL-C) and TG as well as low 
levels of HDL-C are well-documented CVD risk factors. 
Lowering total and LDL-C levels has clearly been shown to 
reduce CVD risk. However, almost one-half of myocardial 
infarctions and strokes occur in people with normal 
LDL-C levels ( 17 ), leading to a search for more specifi c 
markers for risk of CVD. Emerging data indicate that more 
detailed characterization of plasma apolipoproteins (apo) 
and lipoprotein subpopulations, including apoA-I, apoA-II, 
apoE, apoB, remnant lipoprotein cholesterol (RLP-C), 
and HDL subpopulations, provides additional informa-
tion regarding CVD risk ( 18–21 ). Specifi c apoA-I-contain-
ing HDL particles (large lipid-rich   -1 and   -2, and small 
lipid-poor pre  -1) were proven to be superior to standard 
lipid measurements in CVD risk assessment in large epide-
miological studies ( 19–21 ). 
 In this study, we tested the hypothesis that signifi cant 
weight loss in morbidly obese women following RYGBP 
surgery induces benefi cial effects not only on body weight, 
body fat, and established CVD risk markers, but also on 
emerging CVD risk markers and HDL remodeling. 
 METHODS 
 Study population 
 We have studied 19 morbidly obese women (mean age 41 ± 8 
years) who underwent RYGBP surgery and 19 age-matched lean 
female controls who had no history of diabetes or cardiovascular, 
kidney, or thyroid disease. The surgery was performed at the Uni-
versity of California Davis Medical Center or at Mercy San Juan 
Hospital in Sacramento, CA. Fasting blood samples were col-
lected prior to and at 1, 3, 6, and 12 months after surgery; body 
composition was assessed at 0, 1, and 12 months at the University 
of California Davis Clinical and Translational Science Center’s 
Clinical Research Center (Mather Field Department of Veterans 
Affairs Medical Center, Rancho Cordova, CA). The Institutional 
Review Board of the University of California Davis approved the 
experimental protocol, and all subjects provided written in-
formed consent to participate in the study. 
 Anthropometric and biochemical measurements 
 Body composition was determined using air-displacement 
plethysmography (BodPod Body composition system, Life Mea-
surements, Concord, CA). Body weight, height, and waist and 
hip circumference were measured by a trained nurse using stan-
dard methods. 
 Total cholesterol (total-C), HDL-C, LDL-C, and TG were 
measured by standard enzymatic methods with kits from Roche 
Diagnostics (Indianapolis, IN). RLP-C was assessed with an 
immuno-separation method using kits from Kyowa Medex (To-
kyo, Japan). HDL-TG was measured after the apoB-containing 
lipoproteins were precipitated by dextran-sulfate-MgCl. Total 
plasma apoA-I, apoA-II, and apoE concentrations were measured 
with turbidimetric immunoassay kits from Wako Diagnostics 
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and RYGBP subjects at baseline, despite the signifi cantly 
lower plasma apoA-I level in RYGBP subjects, and did not 
change after surgery/weight loss. 
 The mean of individual changes of the measured pa-
rameters from baseline over time (at 1, 3, 6, and 12 
months) are presented in  Table 2 . As expected and re-
ported earlier ( 16, 27 ), BMI decreased progressively after 
RYGBP surgery. Plasma glucose decreased signifi cantly at 
3 months (  10%) and remained lowered. Insulin (  36%) 
and HOMA-IR (  38%) decreased at 1 month after sur-
gery and progressively decreased further over the 12 
month follow-up period. LDL-C (  8%,   4%,   6%, and 
  15%), TG (  3%,   9%,   15%, and   20%), and HDL-
TG (  14%,   24%,   27%, and   34%) levels also 
showed improvement during the studied time course. 
RLP-C decreased by   20% at 1 month and remained de-
creased by this proportion over 12 months after surgery. 
Postoperative changes of HDL-C followed a U-shaped 
curve: there was a signifi cant decrease from baseline at 1 
month, followed by increases at each time point, reaching 
signifi cantly elevated levels compared with baseline at 12 
19 morbidly obese women before (baseline) and 12 
months after RYGBP surgery compared with age-matched, 
healthy, normal-weight control subjects as reference are 
presented in  Table 1 . RYGBP patients, at baseline, had sig-
nifi cantly lower plasma concentrations of total-C, LDL-C, 
HDL-C, apoA-I, and apoA-II and signifi cantly higher 
plasma concentrations of TG and RLP-C than control 
subjects. At 12 months after surgery, RYGBP patients ex-
hibited marked reductions of BMI, fat mass, and lean 
mass. In addition, plasma TG, RLP-C, and apoE levels, as 
well as glucose, insulin, and HOMA-IR, were also re-
duced, whereas HDL-C level was signifi cantly increased 
compared with baseline levels. Among the apoA-I-con-
taining HDL subpopulations, mean baseline concentra-
tions of large   - and pre  -mobility HDL particles (  -1, 
  -2, pre  -1, and pre  -2) were signifi cantly lower in 
RYGBP patients before surgery than in control subjects. 
Of these parameters, mean concentrations of   -1 and 
pre  -1 increased signifi cantly at 12 months after surgery. 
Plasma concentrations of small HDL particles (  -3,   -4, 
pre  -3, and pre  -4) were comparable between controls 
 TABLE 1. Characteristics of morbidly obese women before and 12 months after gastric bypass surgery 
and of age-matched healthy control subjects 
Gastric Bypass Patients (n = 19)
Variable Controls (n = 19) Baseline 12 months
Age (year) 44 ± 4 41 ± 8 42 ± 8
BMI (kg/m 2 ) 25 ± 4 46 ± 8  a 31 ± 5 ab 
Fat mass (kg) NA 67 ± 15 33 ± 8 b 
Lean mass (kg) NA 63 ± 14 46 ± 5 b 
Waist/hip ratio 0.82 ± 0.1 0.95 ± 0.1 a 0.88 ± 0.1 ab 
Fasting glucose 84 ± 10 100 ± 20 a 83 ± 5 b 
Fasting insulin (IU) 9 ± 7 33 ± 16 a 11 ± 3 ab 
HOMA-IR 1.7 ± 0.8 8.5 ± 5.7 a 2.3 ± 0.7 ab 
Total-C 203 ± 48 147 ± 31 a 133 ± 24 a 
LDL-C 121 ± 41 98 ± 29 a 81 ± 19 ab 
HDL-C 59 ± 14 37 ± 10 a 46 ± 8 ab 
LDL/HDL 2.2 ± 1.0 2.6 ± 0.7 1.9 ± 0.5 b 
HDL-TG a NA 19.4 ± 7.5 15.5 ± 5.3 b 
TG a 112 ± 58 141 ± 105 a 84 ± 51 b 
RLP-C 4.7 ± 2.4 7.4 ± 6.7 a 4.0 ± 3.6 b 
Apo A-I 156 ± 23 108 ± 25 a 117 ± 26
Apo A-II 37 ± 8 24 ± 5 a 23 ± 5 a 
Apo E 4.0 ± 0.8 3.6 ± 0.9 2.8 ± 0.6 ab 
LCAT mass (µg/ml) NA 9.3 ± 2.1 7.4 ± 1.6 b 
LCAT activity b NA 3.9 ± 1.0 2.7 ± 1.4 b 
CETP mass (µg/ml) NA 1.0 ± 0.3 1.1 ± 0.3
CETP activity c NA 16.5 ± 19.2 2.8 ± 18.8 b 
ApoA-I-containing HDL subpopulations
 Pre  -1 12.4 ± 6.5 14.3 ± 9.7 11.5 ± 7.3 b 
 Pre  -2 2.3 ± 1.4 2.2 ± 1.7 1.9 ± 1.4
   -1 27.4 ± 9.2 9.0 ± 4.7 a 17.3 ± 5.1 ab 
   -2 55.9 ± 11.0 39.1 ± 11.2 a 42.7 ± 11.0
   -3 28.9 ± 4.7 24.8 ± 7.3 20.8 ± 7.9
   -4 10.0 ± 3.1 10.4 ± 3.8 9.6 ± 4.0
 Pre  -1 7.2 ± 3.2 1.9 ± 1.6 a 4.2 ± 2.4 ab 
 Pre  -2 8.0 ± 2.8 3.6 ± 1.8 a 4.8 ± 2.4 a 
 Pre  -3 1.9 ± 0.4 1.9 ± 0.8 1.7 ± 0.8
 Pre  -4 1.0 ± 0.3 0.9 ± 0.5 0.9 ± 0.3
Values are mean ± SD (mg/dl) or as indicated.  P   0.01 was selected as signifi cantly different (Student’s  t -test). 
Letters indicate statistically signifi cant difference from: (a) controls, (b) baseline. Conversion factor from mg/dl to 
mmol: for cholesterol, divide numbers by 38.88; for TG, divide numbers by 86.88.
 a Statistical test performed using log transformed values.
 b µg/ml/h CE increase in plasma.
 c µg/ml/h CE decrease in HDL.
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17.3 mg/dl, which was still lower than normal, but the sub-
jects’ weights were still signifi cantly above normal. 
 Correlations between proportional (percent) changes 
from baseline to 12 months for lipoprotein, obesity, and 
glucose homeostasis variables based on matrix analysis are 
presented in  Table 3 . There were signifi cant positive as-
sociations between changes of BMI and LDL-C ( r = 0.520; 
 P = 0.018), changes of fat mass and LDL-C ( r = 0.52;  P = 
0.018), and changes of fat mass and LCAT mass ( r = 0.569; 
 P = 0.011). Changes of plasma insulin level were positively 
correlated with changes of LCAT mass ( r = 0.475;  P = 0.043) 
and inversely with changes of large   -1 ( r =   0.498;  P = 
0.030) and   -2 ( r =   0.445;  P = 0.050) HDL particle levels. 
Changes of plasma glucose concentration were inversely 
correlated with changes of CETP mass ( r =   0.629;  P = 
0.005) and   -1 HDL particle levels ( r =   0.641;  P = 0.004). 
Changes of insulin resistance (HOMA-IR) were inversely 
correlated with changes of CETP mass ( r =   0.520;  P = 
0.031) and   -1 HDL particle levels ( r =   0.548;  P = 0.018) 
and positively with changes of LCAT mass ( r = 0.472;  P = 
0.044). The changes in TG were positively associated with 
RLP-C ( r = 0.719;  P = 0.002), apoE ( r = 0.529;  P = 0.029) and 
LCAT mass ( r = 0.476;  P = 0.040) and inversely with   -2 HDL 
particle ( r =   0.458;  P = 0.042) levels. 
 Moreover, changes in waist circumference were associ-
ated positively with changes in HDL-TG ( r = 0.457;  P = 
0.043) and tended to be inversely associated with changes 
months. ApoA-I and apoA-II levels initially decreased then 
returned to baseline levels at 3 months and remained at 
that level. The apoE level was signifi cantly decreased at 3 
months and remained signifi cantly lower than baseline for 
the remaining 9 months. CETP mass fi rst decreased (mean 
change   31%) at 1 month, then continually increased 
with a 13% increase [nonsignifi cant (NS)] above baseline 
level at 12 months. At the same time, CETP activity con-
tinually decreased after the surgery (mean changes from 
baseline   17%,   27%,   57%, and   83%). Both LCAT 
mass and activity decreased signifi cantly at 1 month and 
then remained at that level. Concentrations of all apoA-I-
containing HDL subpopulations (except pre  -2) were 
lower at 1 month compared with baseline, refl ecting the 
reduction in total plasma apoA-I level at that time. At 12 
months, HDL particle concentrations increased, although 
not uniformly. The mean individual changes of small, 
lipid-poor pre  -1,   -4, and   -3 particles from baseline to 
any sampling time were not signifi cant, whereas the mean 
individual changes of large, lipid-rich   -1 and   -2 particles 
from baseline were signifi cant at each sampling time and 
increased by 177% and 22% at 12 months, respectively. 
 Figure 1 illustrates changes in the HDL subpopulation 
profi le of a representative subject at baseline and at 12 months. 
At baseline, the average   -1 level of obese subjects was 9 
mg/dl versus 27.4 mg/dl of lean subjects. After an average 
34 kg fat mass loss, the mean   -1 concentration increased to 
 TABLE 2. Mean percent changes (± SD) of variables of 19 severely obese women following gastric bypass 
surgery compared with baseline values 
Variable 1 Month 3 Month 6 Month 12 Month
BMI   10 ± 2 a   18 ± 4 ab   25 ± 5 abc   32 ± 6 bcd 
Fat mass   12 ± 3 a NA NA   51 ± 11 ab 
Lean mass   10 ± 4 a NA NA   16 ± 13 ab 
Waist/hip ratio   5 ± 9   6 ± 7 a   7 ± 9 ab   6 ± 9 a 
Glucose   7 ± 12   10 ± 12 a   13 ± 12 ab   14 ± 14 ab 
Insulin   36 ± 37 a   49 ± 20 ab   57 ± 17 ab   59 ± 18 ab 
HOMA-IR   38 ± 42 a   53 ± 22 a   62 ± 18 ab   63 ± 18 ab 
Total-C   10 ± 24   3 ± 26   4 ± 23   7 ± 15
LDL-C   8 ± 31   4 ± 30   6 ± 28   15 ± 19
HDL-C   16 ± 24 a   2 ± 20 b 8 ± 20 bc 15 ± 20 abcd 
LDL/HDL 12 ± 29   11 ± 15 b   10 ± 19 b   10 ± 20 b 
HDL-TG a   14 ± 29   24 ± 27 a   27 ± 26 a   34 ± 27 ab 
TG a   3 ± 51   9 ± 67   15 ± 56 ab   20 ± 61 ab 
RLP-C   19 ± 50 a   16 ± 57 a   22 ± 56 a   21 ± 72 a 
Apo A-I   24 ± 20 a   6 ± 26 b 3 ± 25 b 9 ± 31 bc 
Apo A-II   21 ± 15 a   14 ± 30 a   4 ± 19 b   6 ± 25 b 
Apo E   11 ± 19   19 ± 28 a   15 ± 17 a   16 ± 18 a 
CETP activity   17 ± 19   27 ± 28 a   53 ± 48 a   83 ± 66 ab 
LCAT activity   33 ± 17 a   22 ± 26 a   17 ± 33 a   24 ± 53 a 
CETP mass   31 ± 13 a   19 ± 19 ab   13 ± 21 13 ± 29 bcd 
LCAT mass   18 ± 16 a   13 ± 17 a   12 ± 20 a   22 ± 13 a 
ApoA-I-containing HDL subpopulations
 Pre  -1   20 ± 46 a   12 ± 67   4 ± 57   1 ± 4 b 
 Pre  -2 70 ± 224 112 ± 228 12 ± 60 30 ± 70
   -1   7 ± 43 68 ± 99 b 115 ± 160 ab 177 ± 180 abc 
   -2   23 ± 22 a   6 ± 26 b 8 ± 31 b 22 ± 42 abc 
   -3   19 ± 32 a   10 ± 29   7 ± 28   10 ± 30
   -4   20 ± 38 a   12 ± 36 2 ± 36 4 ± 51
 Pre  -1   52 ± 238 159 ± 319 251 ± 416 b 580 ± 920 abc 
 Pre  -2   6 ± 54 20 ± 81 b 47 ± 63 ab 75 ± 99 abc 
 Pre  -3   5 ± 48 2 ± 48 9 ± 64   2 ± 51
 Pre  -4   7 ± 45 9 ± 55 5 ± 69 17 ± 58
Letters indicate statistically signifi cant difference from: (a) baseline, (b) 1 month, (c) 3 month, (d) 6 month 
(two-sided  P < 0.05, Tukey’s Honestly Signifi cant Difference).
 a Differences were determined from analyses of log-transformed data.
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tribution of apoA-IV-containing particles in obese subjects 
at baseline was similar to those in controls and did not 
change in the 12 month follow-up (data not shown). On 
the other hand, morbidly obese RYGBP patients had more 
small apoE-containing HDL particles at baseline than con-
trols, and the dominance of small apoE-containing parti-
cles remained unchanged (data not shown), although 
plasma apoE concentrations decreased signifi cantly at 12 
months postsurgery ( Table 1 ). 
 DISCUSSION 
 Previous epidemiologic studies have reported that obe-
sity is an independent CVD risk factor ( 28, 29 ). However, 
the pathophysiological mechanisms underlying this asso-
ciation are not clear. The goal of this study was to follow 19 
morbidly obese women prior to and for 12 months follow-
ing RYGBP surgery and examine changes in markers of 
lipid and glucose metabolism associated with substantial 
weight loss. Samples were collected from RYGBP patients 
before (baseline) and at 1, 3, 6, and 12 months after sur-
gery, providing an opportunity to investigate the time 
course of changes of the measured parameters. 
 In accordance with others ( 30, 31 ), we observed normal 
baseline total cholesterol and LDL-C levels (mean = 98 
mg/dl) in these obese women. Baseline TG concentrations, 
although signifi cantly higher than in normal-weight con-
trol subjects, were generally within the normal range (<150 
mg/dl). However, we observed a 25% higher pre  -1 level 
along with a 66% lower   -1 HDL level in morbidly obese 
subjects before surgery compared with control subjects, 
indicating an abnormal HDL remodeling and maturation 
process. Overall, the HDL subpopulation profi le of obese 
subjects was similar to that we have reported in subjects 
with established CVD ( 25 ). We have documented in sev-
eral populations that an HDL subpopulation profi le 
in HDL-C ( r =   0.376; NS). Changes in HDL-TG had a 
signifi cant positive association with changes in total TG 
( r = 0.671;  P = 0.008) and NS positive associations with changes 
in HDL-C ( r = 0.225), apoA-I ( r = 0.425), apoE ( r = 0.443), 
and insulin ( r = 0.316) levels. Changes in HDL-TG had a 
tendency to be associated positively with changes in the 
levels of small   -4 HDL particles ( r = 0.316, NS) and in-
versely with changes in the large   -1 HDL particles ( r = 
  0.333, NS) (data for these associations are not shown). 
 The distribution of apoA-IV- and apoE-containing HDL 
particles was also assessed by nondenaturing 2-dimensional 
gel analysis, immunoblotting, and image-analysis. The dis-
 Fig.  1. ApoA-I-containing HDL subpopulations of a representa-
tive subject before and 12 month after GBP surgery. Baseline val-
ues: HDL-C, 41.5 mg/dl; apoA-I, 124 mg/dl; TG, 214 mg/dl;   -1 
HDL, 10.4 mg/dl; and   -2 HDL, 28.2 mg/dl. Values at 12 months: 
HDL-C, 48.1 mg/dl; apoA-I, 129 mg/dl; TG, 128 mg/dl;   -1, 22.7 
mg/dl; and   -2 HDL, 34.5 mg/dl. While HDL-C and apoA-I levels 
increased 16% and 4%, there was a redistribution of apoA-I-con-
taining HDL particles toward large particles with 117% and 22% 
increases in   -1 and   -2 levels. 
 TABLE 3. Correlations between changes (percentile) from baseline to 12 months of lipoprotein parameters 
with BMI, fat mass, TG, fasting glucose and insulin, and HOMA-IR 
Variable BMI Fat Mass TG Insulin Glucose HOMA-IR
LDL-C 0.520 (0.018) 0.520 (0.018)   0.133 0.047   0.409   0.102
HDL-C 0.171 0.160   0.270 0.025 0.022 0.030
TG 0.410 0.251 — 0.065 0.154 0.100
RLP-C 0.453 0.054 0.719  (0.002) 0.170 0.171 0.056
apoA-I 0.053   0.040 0.022   0.233 0.041   0.062
apoA-II 0.159 0.117   0.079   0.159 0.234   0.083
Apo E 0.319   0.215 0.523  (0.029)   0.081 0.092 0.019
CETP mass 0.060 0.034 0.112   0.322 –0.629 (0.005) –0.520 (0.031) 
CETP activity 0.019 0.012 0.049 0.030   0.217   0.110
LCAT mass 0.392 0.569 (0.011) 0.476  (0.040) 0.475 (0.043) 0.324 0.472 (0.044) 
LCAT activity 0.111 0.050 0.069 0.100 0.010 0.078
Pre  -1 0.035 0.015 0.205   0.194   0.111   0.200
Pre  -2 0.242 0.112   0.216   0.367   0.108   0.333
  -1   0.030   0.033   0.353 -0.498 (0.030) -0.641 (0.004) -0.548  (0.018) 
  -2   0.140   0.165 –0.458  (0.042) -0.445 (0.050)   0.076   0.430
  -3   0.100   0.206 0.032   0.187   0.113   0.174
  -4 0.085   0.100 0.414   0.171   0.228   0.209
Pre  -1 0.010 0.038   0.071   0.339   0.244   0.339
Pre  -2 0.076 0.047   0.376   0.445 0.242   0.365
Pre  -3   0.086   0.208 0.013   0.114 0.171   0.054
Pre  -4 0.028   0.140 0.010   0.096   0.084   0.106
Values represent  r values; values in parenthesis represent  P -values. An  r value > 0.44 was considered signifi cant 
with a  P -value < 0.05.
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The associations between HDL-TG and HDL particles in-
dicated that only LpA-I HDL particles were associated with 
HDL-TG level: the large LpA-I   -1 particles displayed an 
inverse relationship with HDL-TG, while the small   -4 was 
positively correlated with HDL-TG. A signifi cant positive 
association observed between HDL-TG and apoE levels in-
dicates a potential role of apoE in TG traffi cking. 
 Although, adipose tissue is a major source of CETP pro-
tein, in this study, changes of CETP mass were not associ-
ated with changes of fat mass. We hypothesize that CETP 
production is more closely related to adipocyte number 
than the lipid content (size) of adipocytes, and weight loss 
does not necessarily promote fat cell loss but mainly de-
creases adipocyte volume. In vivo, CETP activity is consid-
ered to be more infl uenced by the concentration of its 
substrates, VLDL and/or specifi c HDL particles, than by 
the concentration of CETP protein ( 32, 36 ). In agreement 
with these publications, we observed that changes of CETP 
activity were independent of changes of CETP mass ( Fig. 
2 ). In this study, we observed a signifi cant inverse associa-
tion between changes in glucose and CETP and   -1 HDL 
particle levels. This observation indicates that glucose ho-
meostasis may also regulate CETP mass. The continuous 
decrease in CETP activity, which was independent of 
change in CETP mass ( Fig. 2 ), was probably secondary to 
quantitative and qualitative changes in VLDL and HDL, 
which both are substrates for CETP activity. These fi ndings 
are in line with those of Dullart ( 37–39 ), who has pub-
lished several papers on associations between glucose ho-
meostasis and PLTP and CETP activities, and of John 
Albers ( 40 ), who published that both mRNA and activity 
of PLTP was regulated by glucose. 
 Limitations of the study include:  1 ) the study was not a 
randomized intervention study;  2 ) the study population in-
cluded only one male subject whose data were omitted; there-
fore the observations in this manuscript may not be applicable 
to men; and  3 ) data on diet, exercise, and alcohol intake 
were not available to be included in the analyses. 
characterized by low levels of   -1 and   -2 and high levels of 
pre  -1 HDL is signifi cantly associated with increased initial 
and recurrent CVD events ( 18–21 ). Furthermore, in the 
HDL-Atherosclerosis Treatment Study, simvastatin + niacin 
combination therapy increased concentrations of large HDL 
particles (  -1 and   -2) and decreased the concentration of 
the small HDL particle (pre  -1), and this shift was signifi -
cantly associated with a slower progression of coronary 
stenosis assessed by angiography ( 18 ). 
 This study allowed a detailed analysis of the changes of 
lipoprotein subclasses and an examination of the relation-
ships between changes of these parameters with changes 
of BMI, fat mass, and glucose homeostasis following weight 
loss. Following RYGBP-induced weight loss, we observed 
signifi cant improvements in the lipoprotein profi le in ad-
dition to the previously reported signifi cant improvements 
in infl ammation and indices of glucose homeostasis ( 27 ). 
We observed signifi cant decreases in LDL-C, plasma TG 
and HDL-TG, RLP-C, and signifi cant increases in HDL-C 
levels, which resulted in marked improvement of the HDL 
subpopulation profi le (a 177% increase in the cardio-pro-
tective   -1 particle level). The changes in HDL subpopula-
tion profi le in postoperative samples indicated a substantial 
improvement in HDL remodeling and likely in HDL func-
tions. HDL particles are implicated in different steps of 
reverse cholesterol transport, a metabolic pathway in-
volved in the removal of cholesterol from macrophages in 
the vessel wall and transportation back to the liver. Pre  -1 
HDL consists of small, lipid-poor particles, containing 
apoA-I without apoA-II, and interacts with cholesterol 
transporter ATP-binding cassette 1 to promote cellular-
lipid effl ux. After picking up FC and phospholipids from 
cells, pre  -1 continually matures into larger, lipid-rich 
HDL particles (  -4,   -3,   -2, and   -1), increasing size and 
lipid content through the action of LCAT and lipoprotein 
lipase ( 32 ). The large, lipid-rich HDL particles,   -1 and 
  -2, directly transport cholesterol to the bile via the he-
patic scavenger receptor class B type I pathway or indirectly 
via apoB-containing particles with the involvement of 
CETP and LDL receptors ( 33 ). A signifi cant increase in 
the levels of large HDL particles, observed during the fol-
low-up, requires more CE accumulation in HDL, which 
might be the result of lower CETP and/or higher LCAT 
activities. ApoA-I, on the surface of HDL, activates LCAT 
that esterifi es FC into CE, the prime core material for the 
large spherical HDL particles. CETP transports CE from 
HDL to VLDL in exchange for TG. The TG-enriched HDL 
is susceptible for hepatic lipase activity, which can result in 
the formation of HDL remnants like the lipid-poor pre  -1 
and   -4 particles ( 34 ). As a result of a decrease in HDL 
size, the fractional catabolic rate of HDL increases ( 35 ), 
which may provide a possible explanation for the lower 
baseline levels of key HDL components (HDL-C, apoA-I, 
and apoA-II) in obese subjects. Because of signifi cant 
weight loss, HDL-C increased and HDL-TG content de-
creased. After weight loss, both CETP and hepatic lipase 
activity decreased and in turn HDL size increased. Changes 
in waist circumference were associated positively with 
changes in HDL-TG and inversely with changes in HDL-C. 
 Fig.  2. Best curve fi t of mean values of CETP and LCAT masses 
and activities obtained from plasma samples collected at baseline 
and at 1, 3, 6, and 12 months following gastric bypass surgery. 
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 In this study, a marked loss of fat mass produced signifi -
cant improvement in the HDL subpopulation profi le, 
which was substantially greater than we had previously re-
ported with drug intervention therapies ( 18, 41 ). Moreover, 
substantial weight loss was accompanied by decreases of 
plasma TG and of the highly atherogenic RLP-C and 
HDL-TG levels and by increases of HDL-C. Together with 
the improvement of glucose homeostasis, these are indicative 
of the improved cardiovascular health/cardiometabolic 
function in these weight-reduced patients.  
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